Skye Bioscience, Inc. (SKYE) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Skye Bioscience, Inc. is a clinical-stage biotechnology company that has paused all research and development (R&D) activities for its lead asset, nimacimab, following the termination of its CBeyond Phase 2a clinical trial. The company is currently in a wind-down phase of legacy operations while pursuing a strategic transaction to acquire Redx Pharma Limited (the "Transaction").
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(23,295,955) | $(28,728,191) |
| Operating Loss | $(23,735,669) | $(30,003,487) |
| Cash Used in Operating Activities | $(15,679,591) | $(19,931,667) |
| Cash and Cash Equivalents (End of Period) | $8,068,357 | $23,838,244 |
| Short-Term Investments | $1,995,784 | $19,854,723 |
| Total Liquidity (Cash + ST Investments) | $10,064,141 | $43,692,967 |
| Working Capital | $(572,215) Deficit | $18,888,688 Surplus |
| Stockholders' Equity (Deficit) | $(497,307) | $43,676,709 |
Material Changes vs. Prior Period
- Significant Reduction in R&D Expenses: R&D expenses decreased by approximately 45% year-over-year (from $21.5M to $11.9M) due to the termination of the CBeyond clinical trial and the pause of nimacimab development. This included a $7.7M reduction in contract manufacturing costs.
- Legal Contingency Increase: The company recognized a $3.25 million charge for a change in estimate regarding the "Cunning Lawsuit" (a wrongful termination case). The total accrued legal contingency liability increased to $5.42 million as of June 30, 2026.
- Asset Impairment: A non-cash impairment loss of approximately $590,000 was recorded for manufacturing assets deemed no longer recoverable due to the strategic pivot.
- Liquidity Shift: While cash burn from operations slowed, total liquidity decreased significantly as the company liquidated short-term investments (maturities of ~$17.9M) to fund operations and reduce the cash balance.
- Equity Position: The company moved from a positive equity position of $20.0M at year-end 2025 to a deficit of $0.5M by June 30, 2026, driven by accumulated losses.
Guidance, Outlook, and Risks
- Strategic Transaction: On August 14, 2026 (subsequent to the period end), Skye entered into a Transaction Agreement to acquire Redx Pharma Limited. The combined entity plans to operate as Fibrx Therapeutics, Inc. This transaction is subject to shareholder and regulatory approvals.
- Concurrent Financing: The company has secured a commitment for a concurrent financing of approximately $67.9 million (potentially up to $72.9 million) to support the transaction and future operations.
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern without the completion of the Redx transaction or additional capital raising. The company estimates it has sufficient capital only through the anticipated closing of the transaction.
- Nasdaq Compliance: The company received notice of non-compliance with Nasdaq's minimum bid price ($1.00) and minimum stockholders' equity requirements. It has transferred listing to the Nasdaq Capital Market (lower equity threshold) and approved a 1-for-8 reverse stock split to address the bid price deficiency.
- Legal Risks: The outcome of the Cunning Lawsuit retrial (scheduled for October 2026) remains uncertain. Additionally, securities class action and derivative lawsuits have been filed regarding statements made about nimacimab.
Investor Verification Checklist
- Transaction Closing Conditions: Verify the status of shareholder approvals and regulatory clearances required for the Redx Pharma acquisition.
- Legal Contingency Exposure: Monitor the status of the Cunning Lawsuit retrial and potential settlement discussions, as the $5.4M accrual may change significantly.
- Reverse Stock Split Execution: Confirm the effective date and market impact of the 1-for-8 reverse stock split intended to regain Nasdaq compliance.
- Financing Terms: Review the definitive terms of the Concurrent Financing and the Equity Line of Credit (ELOC) with Redmile Group to understand dilution and future capital obligations.
- Asset Monetization: Assess the likelihood of monetizing "Legacy Assets" (nimacimab IP) to generate value for the Contingent Value Rights (CVRs) issued to existing shareholders.